Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
MWN-AI** Summary
Simulations Plus, Inc. (Nasdaq: SLP), a leader in AI-accelerated drug development, is set to host a crucial panel discussion titled “From Debate to Deployment: Responsible, Practical AI in MIDD” at the 2026 American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting on March 5, 2026, in Denver, Colorado. This event aims to navigate the practical implementation of artificial intelligence (AI) in model-informed drug development (MIDD), emphasizing responsible and accountable use amidst increasing industry reliance on AI technologies.
Dr. Viera Lukacova, Chief Scientific Officer at Simulations Plus and moderator of the panel, expressed the urgency of establishing frameworks for responsible AI deployment in drug development, highlighting that the focus has shifted from questioning its use to understanding how to apply it effectively. The panel will feature prominent industry and regulatory leaders, including representatives from the FDA, Genmab, Incyte, Pfizer, and Bristol Myers Squibb, who will share insights drawn from their extensive experiences.
Key discussion points will include the current tangible impacts of AI in workflows, decision-making surrounding organizational strategies for AI integration, and the regulatory principles shaping AI-enabled drug development. Additionally, the panel will address the human dimensions of AI, emphasizing the importance of expert judgment and the evolving skill sets required for scientists in an AI-rich environment.
John DiBella, Chief Revenue Officer of Simulations Plus, highlighted the need for actionable insights, as the scientific community seeks to move beyond theoretical discussions to practical applications of AI. This panel represents Simulations Plus's commitment to integrating AI into core scientific workflows, enhancing efficiency while maintaining rigor under regulatory scrutiny. Attendees are encouraged to arrive early, as space is limited for this engaging and informative session.
MWN-AI** Analysis
Simulations Plus, Inc. (Nasdaq: SLP) is poised for significant growth as it spearheads discussions on the practical implementation of artificial intelligence (AI) in drug development. The upcoming panel at the ASCPT Annual Meeting promises to address critical factors influencing AI adoption, making it a potential catalyst for investor interest.
The pharmaceutical industry is recognizing the shift from theoretical discussions about AI's potential to concrete applications that can enhance model-informed drug development (MIDD). Key insights from industry leaders on the current impact of AI could help stakeholders understand its benefits while navigating the complexities of compliance and integration. As Dr. Viera Lukacova emphasizes, responsible AI use isn't just a trend; it is becoming integral to biopharma innovation.
Investors should pay close attention to Simulations Plus as the company consolidates its position as a leader in AI-accelerated drug development. The diverse expertise on the panel—from regulatory to pharmacology—indicates that the insights shared will cover a wide spectrum of strategic considerations, including building partnerships to enhance capabilities and improving operational workflows.
As AI continues to evolve, companies like Simulations Plus, which are integrating this technology into their core operations, may find themselves ahead of competitors. The emphasis on both technological and human aspects of AI application ensures a holistic approach, enhancing the likelihood of successful implementation.
However, potential investors should remain cautious and consider the risks associated with the volatile nature of regulatory frameworks and market acceptance. Forward-looking statements from the company indicate optimism, but variables like client spending levels and compliance risks remain pertinent. Thus, while Simulations Plus shows promise, maintaining a balanced perspective regarding market dynamics and strategic execution is crucial for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Expert panel at the 2026 ASCPT Annual Meeting brings together leaders with industry and regulatory experience to explore practical, accountable AI implementation
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a high-impact panel discussion, “From Debate to Deployment: Responsible, Practical AI in MIDD,” to be held during the upcoming American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting on March 5, 2026 at 12:00 PM MST in Denver, CO.
“There is no longer a question of whether artificial intelligence (AI) should be used in drug development, but how to implement it responsibly, defensibly, and with measurable value,” said Dr. Viera Lukacova, Chief Scientific Officer of Simulations Plus and moderator of the panel. “We are excited to bring together leaders who can share perspectives influenced by their industry and regulatory experiences to discuss the cost and impact that should be considered by scientists, stakeholders and leaders involved in AI decision-making and implementation.”
During the session, panelists will discuss how AI is currently being deployed as part of model-informed drug development (MIDD) workflows. The session will focus on:
- Where AI is delivering measurable impact today
- How organizations are navigating strategic decisions around building, buying, or partnering to enable sustainable implementation
- The regulatory principles shaping AI-enabled development strategies
Beyond technology, the session will also address the human dimensions of AI integration, discussing where expert judgment is still central, how scientific roles and workflows are adapting to this technology, and the skills scientists will need to succeed in an increasingly AI-enabled future.
“So much of the conversation around AI revolves around abstract future potential, but we recognize that scientists and stakeholders need practical and operational insights they can put to use now,” said John DiBella, Chief Revenue Officer of Simulations Plus. “Our product strategy is centered on integrating AI directly into our core engines and model-informed workflows where it enhances scientific judgment, improves efficiency, and stands up to regulatory scrutiny. This panel is an extension of that commitment, and we are excited to help the industry move from discussion to disciplined deployment.”
Panelists include:
- Rajanikanth Madabushi, Associate Director for Guidance and Scientific Policy, Office of Clinical Pharmacology, CDER/FDA
- Jeff Barrett, Vice President, Clinical Pharmacology & Quantitative Science, Genmab
- John Mondick, Head of Clinical and Quantitative Pharmacology, Incyte
- Mohamed Shahin, AI Strategy Lead, Pfizer
- Yue Zhao, Director, Pharmacometrics, Bristol Myers Squibb
- Amparo de la Peña, Vice President, Pharmacometric Services, Simulations Plus
- Susie Zhang, Vice President, Regulatory Strategies, Simulations Plus
The panel will be held during the ASCPT Annual Meeting in room Summit 9. Interested attendees are encouraged to arrive early as space is limited.
About Simulations Plus, Inc.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com .
Forward-Looking Statements
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “expect,” “anticipate,” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions, or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements include but are not limited to statements regarding our fiscal year 2026 guidance, revenue growth, anticipated margins and profitability, demand to software and services, the impact of pricing actions, client spending levels, market conditions, the development, capabilities, regulatory acceptance, regulatory compliance and commercialization of AI-enabled and could-based solutions, the timing and content of product initiatives discussed at Investor Day, and our ability to execute our long-term strategic vision. These forward-looking statements are based on current assumptions and expectations that involve risks and uncertainties that could cause the actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our internal operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual, and current reports and filed with the U.S. Securities and Exchange Commission. No regulatory authority has endorsed, approved, or validated the Company’s products, platforms, or AI-related approaches.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260303486283/en/
Investor Relations Contact :
Lisa Fortuna
Financial Profiles
310-622-8251
slp@finprofiles.com
FAQ**
How does Simulations Plus Inc. SLP plan to address potential regulatory challenges related to AI integration in drug development during the ASCPT Annual Meeting panel discussion?
What measurable impacts of AI in model-informed drug development will Simulations Plus Inc. SLP highlight at the upcoming ASCPT Annual Meeting?
Can you elaborate on how Simulations Plus Inc. SLP is navigating strategic decisions around AI implementation in drug development workflows?
What specific skills will scientists need to adapt to the integration of AI technologies, as discussed by Simulations Plus Inc. SLP at the ASCPT panel?
**MWN-AI FAQ is based on asking OpenAI questions about Simulations Plus Inc. (NASDAQ: SLP).
NASDAQ: SLP
SLP Trading
2.93% G/L:
$12.29 Last:
66,161 Volume:
$12.10 Open:
